Daratumumab triplet therapies in patients with relapsed or refractory multiple myeloma: A “real world” experience

We report our retrospective analysis on 34 relapsed/refractory multiple myeloma (RRMM) patients treated with daratumumab based triplets. Twenty patients were females and 14 males. Median age was 73.2. Daratumumab was associated to lenalidomide in and dexamethasone (DRd) in 30 (88,3%) and to bortezom...

Descripción completa

Detalles Bibliográficos
Autores principales: Fucci, Ludovica, Gensini, Lorenzo, Coppetelli, Ugo, La Barbera, Elettra Ortu, Gentile, Martina, Fiori, Luciano, Perrone, Salvatore, Cimino, Giuseppe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9184873/
https://www.ncbi.nlm.nih.gov/pubmed/35694449
http://dx.doi.org/10.1016/j.lrr.2022.100330
_version_ 1784724625025925120
author Fucci, Ludovica
Gensini, Lorenzo
Coppetelli, Ugo
La Barbera, Elettra Ortu
Gentile, Martina
Fiori, Luciano
Perrone, Salvatore
Cimino, Giuseppe
author_facet Fucci, Ludovica
Gensini, Lorenzo
Coppetelli, Ugo
La Barbera, Elettra Ortu
Gentile, Martina
Fiori, Luciano
Perrone, Salvatore
Cimino, Giuseppe
author_sort Fucci, Ludovica
collection PubMed
description We report our retrospective analysis on 34 relapsed/refractory multiple myeloma (RRMM) patients treated with daratumumab based triplets. Twenty patients were females and 14 males. Median age was 73.2. Daratumumab was associated to lenalidomide in and dexamethasone (DRd) in 30 (88,3%) and to bortezomib and dexamethasone (DVd) in 4 cases (11,7%). The ORR was 88%. CR occurred in 12% of cases, VGPR in 44% and PR in 32%. The 12 months PFS and OS rates were 78% and 86,5%, respectively. Present data confirm those recently reported in the literature and further reinforce the early use of daratumumab-based triplets for RRMM patients.
format Online
Article
Text
id pubmed-9184873
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-91848732022-06-11 Daratumumab triplet therapies in patients with relapsed or refractory multiple myeloma: A “real world” experience Fucci, Ludovica Gensini, Lorenzo Coppetelli, Ugo La Barbera, Elettra Ortu Gentile, Martina Fiori, Luciano Perrone, Salvatore Cimino, Giuseppe Leuk Res Rep Article We report our retrospective analysis on 34 relapsed/refractory multiple myeloma (RRMM) patients treated with daratumumab based triplets. Twenty patients were females and 14 males. Median age was 73.2. Daratumumab was associated to lenalidomide in and dexamethasone (DRd) in 30 (88,3%) and to bortezomib and dexamethasone (DVd) in 4 cases (11,7%). The ORR was 88%. CR occurred in 12% of cases, VGPR in 44% and PR in 32%. The 12 months PFS and OS rates were 78% and 86,5%, respectively. Present data confirm those recently reported in the literature and further reinforce the early use of daratumumab-based triplets for RRMM patients. Elsevier 2022-05-30 /pmc/articles/PMC9184873/ /pubmed/35694449 http://dx.doi.org/10.1016/j.lrr.2022.100330 Text en © 2022 The Authors. Published by Elsevier Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Article
Fucci, Ludovica
Gensini, Lorenzo
Coppetelli, Ugo
La Barbera, Elettra Ortu
Gentile, Martina
Fiori, Luciano
Perrone, Salvatore
Cimino, Giuseppe
Daratumumab triplet therapies in patients with relapsed or refractory multiple myeloma: A “real world” experience
title Daratumumab triplet therapies in patients with relapsed or refractory multiple myeloma: A “real world” experience
title_full Daratumumab triplet therapies in patients with relapsed or refractory multiple myeloma: A “real world” experience
title_fullStr Daratumumab triplet therapies in patients with relapsed or refractory multiple myeloma: A “real world” experience
title_full_unstemmed Daratumumab triplet therapies in patients with relapsed or refractory multiple myeloma: A “real world” experience
title_short Daratumumab triplet therapies in patients with relapsed or refractory multiple myeloma: A “real world” experience
title_sort daratumumab triplet therapies in patients with relapsed or refractory multiple myeloma: a “real world” experience
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9184873/
https://www.ncbi.nlm.nih.gov/pubmed/35694449
http://dx.doi.org/10.1016/j.lrr.2022.100330
work_keys_str_mv AT fucciludovica daratumumabtriplettherapiesinpatientswithrelapsedorrefractorymultiplemyelomaarealworldexperience
AT gensinilorenzo daratumumabtriplettherapiesinpatientswithrelapsedorrefractorymultiplemyelomaarealworldexperience
AT coppetelliugo daratumumabtriplettherapiesinpatientswithrelapsedorrefractorymultiplemyelomaarealworldexperience
AT labarberaelettraortu daratumumabtriplettherapiesinpatientswithrelapsedorrefractorymultiplemyelomaarealworldexperience
AT gentilemartina daratumumabtriplettherapiesinpatientswithrelapsedorrefractorymultiplemyelomaarealworldexperience
AT fioriluciano daratumumabtriplettherapiesinpatientswithrelapsedorrefractorymultiplemyelomaarealworldexperience
AT perronesalvatore daratumumabtriplettherapiesinpatientswithrelapsedorrefractorymultiplemyelomaarealworldexperience
AT ciminogiuseppe daratumumabtriplettherapiesinpatientswithrelapsedorrefractorymultiplemyelomaarealworldexperience

Ejemplares similares